menu

Keeping Pace in GU Cancers: Clinical Considerations for Prostate Cancer – Global Perspectives

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Keeping Pace in GU Cancers: Clinical Considerations for Prostate Cancer – Global Perspectives

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Prostate cancer is the second most common cancer in incidence and the fifth most frequent cause of cancer-related mortality in men worldwide. With the broader availability of PSA screenings, the incidence of disease is only rising.

    This lively discussion focused on prostate cancer is designed to help you keep pace in GU cancers. You will enhance your knowledge and skills related to targeted therapy in patients with metastatic castrate-resistant prostate cancer, discover relevant biomarkers in prostate cancer, follow a patient case example, and hear about the latest clinical trial data presented at ASCO and ESMO 2021.

    The prostate cancer landscape is rapidly evolving, so tune in to find out what changes you can make in your daily practice today. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Johann de Bono, MD, PhD
    Professor, The Institute of Cancer Research
    University of London
    London, UK

    Salary: The Institute of Cancer Research, University of London
    Consulting Fees: AstraZeneca, Bayer, Daiichi Sankyo, Merck Serono, Sharp & Dohme, Roche
    Contracted Research: Myovant

    Alicia K. Morgans, MD, MPH
    Genitourinary Medical Oncologist
    Dana-Farber Cancer Institute
    Boston, MA 

    Consulting Fees: AAA, Astellas, AstraZeneca, Bayer, Clovis, Dendreon, Janssen, Lantheus, Myovant, Merck, Novartis, Pfizer, Sanofi, Seagen
    Contracted Research: Astellas, Bayer, Myovant, Sanofi, Seagen

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nicole Fox, DNP, MSN-Ed, RN, OCN, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the importance of identifying patient types that will benefit from tumor biopsy and molecular and genetic testing during treatment selection for men with mCRPC
    • Apply current and clinically relevant data into clinical practice for patients with mCRPC
    • Demonstrate the application of current clinical evidence focused on the management of mCRPC using a patient case-based approach
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, urologists, and pathologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) designates this DecisionSim activity for a maximum 0.25 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 Nursing contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  • Provider(s)/Educational Partner(s)

    AGILEAcademy for Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”  

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Prostate cancer is the second most common cancer in incidence and the fifth most frequent cause of cancer-related mortality in men worldwide. With the broader availability of PSA screenings, the incidence of disease is only rising.

    This lively discussion focused on prostate cancer is designed to help you keep pace in GU cancers. You will enhance your knowledge and skills related to targeted therapy in patients with metastatic castrate-resistant prostate cancer, discover relevant biomarkers in prostate cancer, follow a patient case example, and hear about the latest clinical trial data presented at ASCO and ESMO 2021.

    The prostate cancer landscape is rapidly evolving, so tune in to find out what changes you can make in your daily practice today. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Johann de Bono, MD, PhD
    Professor, The Institute of Cancer Research
    University of London
    London, UK

    Salary: The Institute of Cancer Research, University of London
    Consulting Fees: AstraZeneca, Bayer, Daiichi Sankyo, Merck Serono, Sharp & Dohme, Roche
    Contracted Research: Myovant

    Alicia K. Morgans, MD, MPH
    Genitourinary Medical Oncologist
    Dana-Farber Cancer Institute
    Boston, MA 

    Consulting Fees: AAA, Astellas, AstraZeneca, Bayer, Clovis, Dendreon, Janssen, Lantheus, Myovant, Merck, Novartis, Pfizer, Sanofi, Seagen
    Contracted Research: Astellas, Bayer, Myovant, Sanofi, Seagen

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nicole Fox, DNP, MSN-Ed, RN, OCN, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the importance of identifying patient types that will benefit from tumor biopsy and molecular and genetic testing during treatment selection for men with mCRPC
    • Apply current and clinically relevant data into clinical practice for patients with mCRPC
    • Demonstrate the application of current clinical evidence focused on the management of mCRPC using a patient case-based approach
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, urologists, and pathologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) designates this DecisionSim activity for a maximum 0.25 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 Nursing contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  • Provider(s)/Educational Partner(s)

    AGILEAcademy for Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”  

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule2 Dec 2021
Webpack App